ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,327Medicare Part D Prescriptions Filled, Including Refills

Rank: 536 out of 3593

$513K Total Retail Price of All Prescriptions

Rank: 600 out of 3593

956 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
22% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 956 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

13% of this provider’s 956 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 8,918 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
SIMVASTATIN 528 453 1 1
LISINOPRIL 516 459 2 2
LEVOTHYROXINE SODIUM 336 309 3 4
ZOLPIDEM TARTRATE 324 293 4 12
AMLODIPINE BESYLATE 318 293 5 3
OMEPRAZOLE 286 252 6 5
CARVEDILOL 265 246 7 23
METFORMIN HCL 253 211 8 6
LOVASTATIN 224 214 9 20
LISINOPRIL-HYDROCHLOROTHIAZIDE 218 197 10 26
HYDROCHLOROTHIAZIDE 218 189 10 10
FUROSEMIDE 196 186 12 9
HYDROCODONE-ACETAMINOPHEN 190 131 S3 13 7
METOPROLOL TARTRATE 190 165 13 8
VERAPAMIL HCL 164 131 10 15 419
TRAMADOL HCL 158 116 16 17
ATENOLOL 157 138 17 11
POTASSIUM CHLORIDE 151 134 18 24
GLIMEPIRIDE 134 106 19 44
ALENDRONATE SODIUM 127 125 20 22
WARFARIN SODIUM 125 114 21 18
ALLOPURINOL 119 107 22 35
CLONIDINE HCL 115 79 23 41
LOSARTAN POTASSIUM 109 107 24 14
MELOXICAM 108 94 25 29
GABAPENTIN 107 90 26 16
DONEPEZIL HCL 101 101 27 31
TAMSULOSIN HCL 99 94 28 33
RANITIDINE HCL 85 70 29 27
PRAVASTATIN SODIUM 82 75 30 13
METHYLPREDNISOLONE 80 72 31 103
METOPROLOL SUCCINATE 76 69 32 19
DOXAZOSIN MESYLATE 73 58 33 63
VERAPAMIL ER 73 59 33 99
TERAZOSIN HCL 72 72 35 115
FINASTERIDE 65 60 36 79
PROAIR HFA 63 59 37 54
DOXYCYCLINE HYCLATE 63 53 37 141
PAROXETINE HCL 62 50 39 62
GEMFIBROZIL 60 57 40 88
CLOPIDOGREL 58 52 41 30
PLAVIX 55 48 42 42
FLUTICASONE PROPIONATE 54 39 43 32
ESTRADIOL 53 31 R 44 174
ACETAMINOPHEN-CODEINE 52 44 S3 45 153
FENOFIBRATE 52 43 45 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 1, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.